FRC
FRC Logo
CommunityMarkets
Sign InGet Access

Connect With Us

Stay updated with our latest research and insights

Fundamental Research Corp Logo

Highly ranked equity research firm providing institutional grade tools and analysis to all investors worldwide. Trusted by global investors for over 20+ years.

20+ Years
Rate us on TrustpilotLeave a review

Policies

  • Privacy Policy
  • Terms of Service
  • Disclaimer

Company

  • About Us
  • Our Team
  • Contact Us
  • Leave a Review

Resources

  • Videos
  • Research Reports
  • Community
  • FAQ
  • How to use the site

Browse

  • Stock Directory
  • Stock Screener
  • Market Intel Weekly
  • Report Archive

Trackers

  • Congress Trading
  • Senate Trading
  • Congress Net Worth
  • Markets

© 2026 Fundamental Research Corp. All Rights Reserved.

Professional investment research since 2003

Home
Strategies
Intel
Analysis
Community
Company ProfileRegeneron Pharmaceuticals, Inc.
  • Company Overview
  • Financial Data
  • Peer Comparison
  • Ownership & News
  • Discussion
REGN
Regeneron Pharmaceuticals, Inc. Stock AnalysisComprehensive stock analysis for Regeneron Pharmaceuticals, Inc. (REGN) including live price, Snowflake performance metrics, financial statements, and investment research.Stock AnalysisREGN
REGN
Regeneron Pharmaceuticals, Inc.
  • Company Overview
  • Financial Data
  • Peer Comparison
  • Ownership & News
  • Discussion
REGN
  1. Home
  2. Stocks
  3. Regeneron Pharmaceuticals, Inc.

Regeneron Pharmaceuticals, Inc.

🇺🇸REGN•NASDAQ

Regeneron Pharmaceuticals, Inc.

🇺🇸REGN•NASDAQ
Market cap
$98.51B
Sentiment

Your view on REGN

Mkt Cap
$98.51B
Sentiment
Your view
Company Overview

Overview

What the company does, where it operates, and who runs it.

About Regeneron Pharmaceuticals, Inc.

Industry
Biotechnology
Sector
Healthcare
CEO
Leonard S. Schleifer
Headquarters
777 Old Saw Mill River Road, Tarrytown, NY, US
Industry
Biotechnology
Sector
Healthcare
CEO
Leonard S. Schleifer
Headquarters
777 Old Saw Mill River Road, Tarrytown, NY, US
Description

Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide.

The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; and diabetic retinopathy, as well as macular edema following retinal vein occlusion, including macular edema following central retinal vein occlusion and macular edema following branch retinal vein occlusion.

It also provides Dupixent injection to treat atopic dermatitis and asthma in adults and pediatrics; Libtayo injection to treat metastatic or locally advanced cutaneous squamous cell carcinoma;Praluent injection for heterozygous familial hypercholesterolemia or clinical atherosclerotic cardiovascular disease in adults; REGEN-COV for covid-19; and Kevzara solution for treating rheumatoid arthritis in adults.

In addition, the company offers Inmazeb injection for infection caused by Zaire ebolavirus; ARCALYST injection for cryopyrin-associated periodic syndromes, including familial cold auto-inflammatory syndrome and muckle-wells syndrome; and ZALTRAP injection for intravenous infusion to treat metastatic colorectal cancer; and develops product candidates for treating patients with eye, allergic and inflammatory, cardiovascular and metabolic, infectious, and rare diseases; and cancer, pain, and hematologic conditions.

It has collaboration and license agreements with Sanofi; Bayer; Teva Pharmaceutical Industries Ltd.; Mitsubishi Tanabe Pharma Corporation; Alnylam Pharmaceuticals, Inc.; Roche Pharmaceuticals; and Kiniksa Pharmaceuticals, Ltd., as well as has an agreement with the U.S. Department of Health and Human Services, as well as with Zai Lab Limited; Intellia Therapeutics, Inc.; Biomedical Advanced Research Development Authority; and AstraZeneca PLC.

The company was incorporated in 1988 and is headquartered in Tarrytown, New York.

Financial Data

Stock Data

Price chart, volume, and trading data.

What moved it

FRC Fair Value Algorithm

What the FRC Fair Value algorithm says it is worth vs. the current price — FRC's own, on every stock.

About this section

Fair value for Regeneron Pharmaceuticals, Inc. from FRC's valuation model, read against the market price. REGN last traded at $952.40, 20.2× trailing earnings — the estimate is read against that market price. The model runs on every stock on the platform and shows the estimate per share and the date it was calculated. A free account covers 3 company valuations a month; a paid subscription is unlimited.

Financial Ratios

Profitability, returns, valuation, and leverage ratios.

About this section

Valuation, profitability, liquidity and leverage ratios for Regeneron Pharmaceuticals, Inc.. Starting points for Regeneron Pharmaceuticals, Inc.: P/E 20.2, EPS $47.37, beta 0.24 — an Biotechnology name. P/E, P/B, EV/EBITDA, margins, return on equity, current ratio and debt coverage, each shown against the company's own history.

Dividend Analysis

Yield, payout ratio, and dividend coverage metrics.

About this section

Dividend history, yield and payout sustainability for Regeneron Pharmaceuticals, Inc.. Regeneron Pharmaceuticals, Inc. paid $3.70 per share over the last year — a 0.4% yield at the current $952.40 price. Per-share payments, yield over time, payout ratio and growth streak, with coverage measured against free cash flow.

Earnings Analysis

EPS history, beat rate, and upcoming earnings reports.

About this section

Reported vs. expected earnings history for Regeneron Pharmaceuticals, Inc.. Trailing twelve-month EPS for Regeneron Pharmaceuticals, Inc. stands at $47.37. EPS surprises by quarter, revenue against estimates, and the upcoming reporting date.

Wall Street Analyst Estimates

Analysts' price targets, ratings, and revenue and EPS estimates.

Third partyAs of Nov 18, 2026 · USD

Price targets, ratings and estimates published by outside analysts. Not FRC research, not a recommendation, and not the FRC Fair Value: that is FRC's proprietary model, built on the cash a company generates.

Current price

—

live quote

Analysts' target

$899.32

average of 25 firms, last 12 months

 

$899.32

Low $756.00

Median $875.00

High $1,100.00

 

Analyst Ratings

Buy25 firms, last 12 months
  • Strong Buy0
  • Buy17
  • Hold8
  • Sell0
  • Strong Sell0

Earnings Estimate

EPSCurrent QtrDec 2026Next QtrMar 2027Current YearFY Dec 2026Next YearFY Dec 2027
Avg. estimate$25.80$15.94$68.23$70.90
Low estimate$15.83$14.79$54.98$60.66
High estimate$31.72$16.60$75.39$78.21
No. of analysts1461510
Year-ago EPS$11.44$9.47$41.481—
Growth+125.5%+68.3%——

1Year-ago EPS includes one-time items; growth not shown.

Revenue Estimate

RevenueCurrent QtrDec 2026Next QtrMar 2027Current YearFY Dec 2026Next YearFY Dec 2027
Avg. estimate$5.85B$4.60B$18.78B$20.15B
Low estimate$4.56B$4.41B$16.48B$17.76B
High estimate$6.28B$4.82B$19.88B$21.60B
No. of analysts1251919
Year-ago revenue$3.88B$3.61B$14.34B—
Growth+50.7%+27.7%+30.9%—
Recent analyst actions15 rating and price-target changes, latest Nov 11, 2026 — with the analyst, firm and source

Source: Wall Street analysts' published price targets, ratings and estimates, compiled by Financial Modeling Prep from StreetInsider, Benzinga, Pulse 2.0; as of Nov 18, 2026. Not FRC research or a recommendation.

Financial Statements

Income statement, balance sheet, and cash flow statements.

About this section

Income statement, balance sheet and cash flow history for Regeneron Pharmaceuticals, Inc.. Regeneron Pharmaceuticals, Inc. has reported as a listed company since 1991. Annual and quarterly filings with period-over-period comparison, so you can trace how revenue, margins and cash generation have moved.

Peer Comparison

Comparables

List of peer companies in the same industry.

Peers, the industry, and the funds that hold REGN20 companies · 8 funds
Compare REGN with its peers, side by sidePremiumRatios, margins, valuation and leverage of the peers below — one table, one glance.Open Comparable Analysis

Peer companies

Market cap

  • AMGNAmgen Inc.Drug Manufacturers - General$250.1B
  • AZNAstraZeneca PLCDrug Manufacturers - General$285.4B
  • BIIBBiogen Inc.Drug Manufacturers - General$37.2B
  • EYPTEyePoint Pharmaceuticals, Inc.Biotechnology$26M
  • GILDGilead Sciences, Inc.Drug Manufacturers - General$207.9B
  • GMABGenmab A/SBiotechnology$31.8B
  • IVBXFInnovent Biologics, Inc.Biotechnology$19.4B
  • NVSNovartis AGDrug Manufacturers - General$302.6B

More Biotechnology companies

  • RNAZTransCode Therapeutics, Inc.NASDAQ$1M
  • RNTXRein Therapeutics Inc.NASDAQ$35M
  • RNUGFReNeuron Group plcOTC$62,891
  • RNXTRenovoRx, Inc.NASDAQ$46M
  • ROIVRoivant Sciences Ltd.NASDAQ$28.0B
  • RVLPQRVL Pharmaceuticals plcOTC$1,114
  • RVMDRevolution Medicines, Inc.NASDAQ$36.1B
  • RVMDWRevolution Medicines, Inc. WarrantNASDAQ$34.1B
  • RVPHReviva Pharmaceuticals Holdings, Inc.OTC$36M
  • RVX.TOResverlogix Corp.TSX$26M
  • RVXCFResverlogix Corp.OTC$23M
  • RXRXRecursion Pharmaceuticals, Inc.NASDAQ$1.8B

ETFs holding Regeneron Pharmaceuticals, Inc.

% of the fund

  • VOOVanguard S&P 500 ETF$1.0T in assets0.14%
  • VTIVanguard Total Stock Market ETF$689.2B in assets0.13%
  • QQQInvesco QQQ Trust, Series 1$446.1B in assets0.46%
  • IVViShares Core SP 500 ETF$852.9B in assets0.15%
  • BBHVanEck Biotech ETF$536M in assets8.08%
  • PBEInvesco Biotechnology & Genome ETF$438M in assets5.92%
  • HHL.TOHarvest Healthcare Leaders Income ETF$2.2B in assets5.41%
  • FBTFirst Trust NYSE Arca Biotechnology Index Fund$3.0B in assets4.26%

Largest holders first, then the funds most concentrated in REGN.

Open Comparable Analysis
Ownership & News

Institutional Ownership

Which funds and firms own the stock.

About this section

Which institutions hold Regeneron Pharmaceuticals, Inc., and how their positions are changing. At a $98.51B market value, institutional positions materially move Regeneron Pharmaceuticals, Inc.'s register. Top holders, position sizes, and quarter-over-quarter accumulation or distribution from regulatory filings.

Insider Trading

Recent buying and selling by company executives.

About this section

Buying and selling by Regeneron Pharmaceuticals, Inc. executives and directors. Shares of Regeneron Pharmaceuticals, Inc. have traded between $476.49 and $800.99 over the past 52 weeks — context for the timing of the transactions below. Insider transactions as disclosed to regulators, with role, size and date — the clearest read on how the people running the company are positioned.

Senate Trading

U.S. Senator disclosures filed under the STOCK Act.

About this section

U.S. Senate disclosures naming Regeneron Pharmaceuticals, Inc.. Regeneron Pharmaceuticals, Inc. is a $98.51B Healthcare company. Senators' reported transactions in this security, alongside the fundamentals — a signal most research platforms leave out entirely.

House Trading

U.S. Representative disclosures filed under the STOCK Act.

About this section

U.S. House of Representatives disclosures naming Regeneron Pharmaceuticals, Inc.. Representatives' reported transactions in this security, shown next to the company's fundamentals.

News

Latest headlines and market coverage.

About this section

Latest headlines and company announcements for Regeneron Pharmaceuticals, Inc.. Coverage tracks Regeneron Pharmaceuticals, Inc. within Biotechnology (Healthcare). Press releases and market coverage, newest first.

Discussion

Comments

Comments and replies from FRC members about this company.

No comments yet

Be the first to ask a question or say what you make of Regeneron Pharmaceuticals, Inc.

REGN Analysis
Strong
Past4
Growth4
Health5
Profit5
Value2

News

Latest Market News